The Sustainability Learning Forum

Paradigm Shift in Vaccines: Our Dengue Vaccine Candidate

Laurent Lhopitallier, Sanofi
Sanofi

Paradigm Shift in Vaccines: Our Dengue Vaccine CandidSanofi Pasteur, the vaccines division of Sanofi, has taken an innovative approach to addressing a disease that affects tropical and subtropical countries, without anticipating a return on investment from high-income countries. For the first time, a new vaccine will have its initial introduction in several middle- and low-income countries – where the need is the greatest. more[...]

The Author

Lhopitallier, Laurent

more[...]

The Author

WHO and Sanofi: A Public-Private Partnership to Save Lives

Dr. Benedict Blayney, Sanofi
Pierre-Guillaume Harscouët, Sanofi
Sanofi

For Sanofi, as a global healthcare partner, improving access to healthcare for the most disadvantaged patients is pivotal to its corporate social responsibility approach. At the core of this commitment is the long-term partnership with the World Health Organization (WHO) to control a group of debilitating infectious diseases, called “neglected tropical diseases,” which affect mostly poor people in developing countries. Since the partnership began, in 2001, more than 20 million people in sub-Saharan Africa have been screened for sleeping sickness, and more than 170,000 patients have received free treatment for what is a fatal disease, if left untreated. This partnership has put the elimination of sleeping sickness within reach – a prospect that was unthinkable a decade ago. more[...]

The Author

Harscouët, Pierre-Guillaume

more[...] login_required

The Author

Blayney, Benedict

more[...] login_required

The Author

Corporate Social Responsibility Reporting 2011

Sanofi

Corporate Social Responsibility encompasses a broad array of issues. This year, Sanofi's CSR Report addresses 48 topics in it's key areas of Patient, Ethics, People and Planet. Each CSR challenge is important. To avoid a situation where it cannot see the forest for the trees, Sanofi has developed a sound CSR organization and applies sophisticated methods to manage the CSR approach across entire the Group. The CSR approach places the patient at the center of the Group’s business. Woven into the fabric of Sanofi’s values and its strategy, CSR principles provide a vision for the future and foster sustainable growth. more[...] login_required

The Author

Providing Know-how

Mireille Cayreyre, Sanofi Aventis

Accessibility and availability of products are as well as the training of good heath care professionals the key problems in rural areas in Africa. We talked about that with Mireille Cayreyre from Sanofi-Aventis. more[...] login_required

The Author

Attacking a Potential Killer of Children

Editorial Team

In 2006, Merck introduced RotaTeq®, its rotavirus vaccine, in the U.S. Merck recognized, however, that this vaccine was most needed in the developing world but that it would be unsustainable to donate it on an ongoing basis – it needed to identify a sustainable business model. Through the Merck-Nicaraguan Ministry of Health RotaTeq® Partnership Merck pledged to donate enough rotavirus vaccine for three birth cohorts of children and funding to introduce the vaccine, improve disease awareness, develop appropriate educational materials, and update the routine vaccination card. Our goal was to demonstrate the feasibility and health benefit of introducing the vaccine in a developing country. more[...] login_required

The Author

Attacking a Potential Killer of Children

Dr. Barbara J. Kuter, Merck
Maggie M. Kohn, Merck
Merck

In 2006, Merck introduced RotaTeq®, its rotavirus vaccine, in the U.S. Merck recognized, however, that this vaccine was most needed in the developing world but that it would be unsustainable to donate it on an ongoing basis – it needed to identify a sustainable business model. Through the Merck-Nicaraguan Ministry of Health RotaTeq® Partnership Merck pledged to donate enough rotavirus vaccine for three birth cohorts of children and funding to introduce the vaccine, improve disease awareness, develop appropriate educational materials, and update the routine vaccination card. Our goal was to demonstrate the feasibility and health benefit of introducing the vaccine in a developing country. more[...]

The Author

Improving the Future of Epileptic Patients

Mireille Cayreyre, Sanofi Aventis
Sanofi

Epilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs. Epilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs. more[...]

The Author